 Sapna Patel
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 36 | 2026 | 761 | 6.990 |
Why?
| | Skin Neoplasms | 17 | 2026 | 847 | 3.090 |
Why?
| | Ipilimumab | 7 | 2025 | 40 | 2.570 |
Why?
| | Uveal Neoplasms | 5 | 2024 | 16 | 2.200 |
Why?
| | Neoadjuvant Therapy | 8 | 2026 | 463 | 1.360 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2023 | 199 | 1.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2025 | 1958 | 1.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 10 | 2026 | 988 | 0.990 |
Why?
| | Programmed Cell Death 1 Receptor | 8 | 2026 | 264 | 0.990 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 241 | 0.940 |
Why?
| | Immunotherapy | 6 | 2026 | 657 | 0.910 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2025 | 20 | 0.880 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1322 | 0.820 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 53 | 0.670 |
Why?
| | Receptor, IGF Type 1 | 1 | 2020 | 64 | 0.650 |
Why?
| | Toll-Like Receptors | 1 | 2021 | 194 | 0.630 |
Why?
| | Dacarbazine | 2 | 2017 | 100 | 0.530 |
Why?
| | Interleukin-2 | 4 | 2025 | 437 | 0.470 |
Why?
| | Neoplasm Staging | 7 | 2024 | 1465 | 0.440 |
Why?
| | CTLA-4 Antigen | 4 | 2023 | 104 | 0.360 |
Why?
| | Choroid Neoplasms | 1 | 2011 | 9 | 0.350 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 2197 | 0.320 |
Why?
| | Quality of Life | 1 | 2023 | 3192 | 0.320 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2025 | 421 | 0.310 |
Why?
| | Quinazolines | 1 | 2011 | 266 | 0.310 |
Why?
| | Middle Aged | 20 | 2026 | 35928 | 0.300 |
Why?
| | Humans | 39 | 2026 | 144957 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 2 | 2016 | 970 | 0.300 |
Why?
| | Male | 23 | 2026 | 72406 | 0.270 |
Why?
| | Aged | 16 | 2026 | 25947 | 0.270 |
Why?
| | Adult | 19 | 2026 | 40506 | 0.270 |
Why?
| | Mucous Membrane | 2 | 2025 | 127 | 0.270 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 695 | 0.260 |
Why?
| | Female | 24 | 2026 | 78376 | 0.240 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8279 | 0.240 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 154 | 0.230 |
Why?
| | Interleukin-7 | 1 | 2026 | 65 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 44 | 0.230 |
Why?
| | Carcinoma, Renal Cell | 2 | 2019 | 234 | 0.220 |
Why?
| | Lymphocyte Depletion | 1 | 2025 | 132 | 0.220 |
Why?
| | Lymph Node Excision | 1 | 2026 | 173 | 0.220 |
Why?
| | Indolizines | 1 | 2024 | 13 | 0.220 |
Why?
| | Cyclic N-Oxides | 1 | 2024 | 33 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
| | Adjuvants, Immunologic | 2 | 2023 | 245 | 0.210 |
Why?
| | Imidazoles | 3 | 2024 | 254 | 0.200 |
Why?
| | Kidney Neoplasms | 2 | 2019 | 412 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 771 | 0.200 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 257 | 0.190 |
Why?
| | Disease-Free Survival | 5 | 2018 | 769 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2017 | 883 | 0.190 |
Why?
| | Immunotherapy, Adoptive | 1 | 2026 | 337 | 0.180 |
Why?
| | Combined Modality Therapy | 3 | 2026 | 1268 | 0.180 |
Why?
| | Prognosis | 6 | 2026 | 4293 | 0.180 |
Why?
| | Dietary Fiber | 1 | 2021 | 59 | 0.170 |
Why?
| | Probiotics | 1 | 2021 | 61 | 0.170 |
Why?
| | Oximes | 2 | 2018 | 26 | 0.170 |
Why?
| | Rare Diseases | 1 | 2021 | 113 | 0.160 |
Why?
| | Pyrimidinones | 2 | 2018 | 126 | 0.160 |
Why?
| | Salvage Therapy | 1 | 2021 | 162 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2026 | 917 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1141 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2023 | 463 | 0.150 |
Why?
| | Pyridones | 2 | 2018 | 199 | 0.150 |
Why?
| | Treatment Outcome | 7 | 2025 | 11695 | 0.140 |
Why?
| | Neoplasms | 3 | 2021 | 2884 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2024 | 783 | 0.130 |
Why?
| | Immunomodulation | 1 | 2016 | 101 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2016 | 163 | 0.110 |
Why?
| | Texas | 2 | 2018 | 278 | 0.110 |
Why?
| | Disease Progression | 1 | 2023 | 2852 | 0.110 |
Why?
| | Mutation | 3 | 2017 | 4099 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 311 | 0.110 |
Why?
| | Survival Rate | 3 | 2026 | 2092 | 0.100 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1524 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 434 | 0.100 |
Why?
| | Genetic Testing | 1 | 2016 | 482 | 0.100 |
Why?
| | Research | 1 | 2016 | 431 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 466 | 0.080 |
Why?
| | Risk Factors | 2 | 2021 | 10792 | 0.080 |
Why?
| | Confidence Intervals | 2 | 2021 | 333 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2026 | 1371 | 0.070 |
Why?
| | Administration, Oral | 1 | 2011 | 848 | 0.070 |
Why?
| | Young Adult | 5 | 2021 | 14126 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2011 | 629 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 966 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2365 | 0.060 |
Why?
| | Cisplatin | 2 | 2021 | 334 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2026 | 139 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3550 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2026 | 334 | 0.050 |
Why?
| | Biomarkers | 1 | 2016 | 4275 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5417 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1385 | 0.050 |
Why?
| | Immunologic Memory | 1 | 2026 | 366 | 0.050 |
Why?
| | New York | 1 | 2023 | 127 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 210 | 0.050 |
Why?
| | Cohort Studies | 3 | 2021 | 5965 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1077 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 280 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2016 | 1718 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2026 | 17101 | 0.040 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2021 | 26 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2021 | 60 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 930 | 0.040 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 21 | 0.040 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 108 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1982 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 115 | 0.040 |
Why?
| | Mice | 3 | 2024 | 18365 | 0.040 |
Why?
| | Hydrolases | 1 | 2021 | 55 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5997 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3676 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 7183 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1048 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 395 | 0.040 |
Why?
| | Feces | 1 | 2021 | 513 | 0.030 |
Why?
| | Mohs Surgery | 1 | 2018 | 29 | 0.030 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 48 | 0.030 |
Why?
| | Standard of Care | 1 | 2018 | 80 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2499 | 0.030 |
Why?
| | Ribosomal Protein S6 | 1 | 2016 | 18 | 0.030 |
Why?
| | Clone Cells | 1 | 2017 | 266 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2016 | 72 | 0.030 |
Why?
| | Gene Dosage | 1 | 2017 | 148 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 509 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2017 | 183 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 138 | 0.030 |
Why?
| | Apoptosis | 1 | 2024 | 2430 | 0.030 |
Why?
| | Animals | 3 | 2024 | 38109 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2021 | 655 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 175 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 292 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 521 | 0.030 |
Why?
| | Macrophages | 1 | 2022 | 1511 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 548 | 0.030 |
Why?
| | Genome | 1 | 2017 | 306 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2016 | 226 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 415 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4569 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2016 | 428 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2014 | 197 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2026 | 6053 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1733 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2032 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1786 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 7997 | 0.010 |
Why?
| | Signal Transduction | 1 | 2016 | 5233 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22453 | 0.010 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|